A preliminary investigation of varenicline for heavy drinking smokers
- 11 January 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Psychopharmacology
- Vol. 215 (4), 655-663
- https://doi.org/10.1007/s00213-010-2160-9
Abstract
Varenicline, an approved smoking cessation pharmacotherapy, also shows promise as a potential treatment for alcohol dependence. However, varenicline has not been tested in heavy drinkers, and it remains to be determined whether varenicline could reduce alcohol craving and consumption in smokers who are trying to quit smoking. We conducted a preliminary study to examine the effect of varenicline on drinking behavior and the effects of extended varenicline pretreatment on smoking. Thirty heavy drinking smokers received smoking cessation counseling and were randomly assigned to receive either an extended 4-week pretreatment with varenicline 2 mg daily or the usual 1-week pretreatment. Those in the extended pretreatment group received active medication for 8 weeks (i.e., 4 weeks of active pre-treatment followed by 4 weeks of active treatment), and participants in the usual pretreatment group received active medication after a placebo lead in (i.e., 3 weeks of placebo followed by active medication for 5 weeks). Participants who received varenicline during the first 3 weeks reported significantly greater reductions in alcohol craving and numerically fewer heavy drinking days compared to those who received placebo, and these differences persisted during the open-label phase. Extended pretreatment was associated with numerically greater reductions in cigarette smoking over the entire study period. There were no differences, however, in smoking abstinence rates following the smoking quit date between the two groups. Findings from this preliminary study suggest that varenicline may be a promising strategy for concurrently reducing heavy drinking and promoting smoking changes in heavy drinkers.This publication has 47 references indexed in Scilit:
- Quitting smoking and change in alcohol consumption in the International Tobacco Control (ITC) Four Country SurveyDrug and Alcohol Dependence, 2010
- Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in micePsychopharmacology, 2010
- Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking SmokersBiological Psychiatry, 2009
- Alcohol consumption and quitting smoking in the International Tobacco Control (ITC) Four Country SurveyDrug and Alcohol Dependence, 2009
- Risk factors for treatment failure in smokers: Relationship to alcohol use and to lifetime history of an alcohol use disorderNicotine & Tobacco Research, 2008
- An Evaluation of μ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol DependenceArchives of General Psychiatry, 2008
- A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gainAddictive Behaviors, 2008
- Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seekingProceedings of the National Academy of Sciences of the United States of America, 2007
- Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a reviewAlcohol and Alcoholism, 2007
- Non-treatment-seeking heavy drinkers: Effects of chronic cigarette smoking on brain structureDrug and Alcohol Dependence, 2007